Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Other research analysts also recently issued reports about the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Syros Pharmaceuticals currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Stock Down 2.2 %

SYRS opened at $0.15 on Tuesday. Syros Pharmaceuticals has a 52-week low of $0.15 and a 52-week high of $7.96. The company has a 50 day moving average of $0.20 and a two-hundred day moving average of $1.06. The company has a market cap of $4.12 million, a P/E ratio of -0.05 and a beta of 1.30.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Exome Asset Management LLC boosted its holdings in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the period. Two Sigma Securities LLC acquired a new position in shares of Syros Pharmaceuticals in the fourth quarter worth about $25,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals in the third quarter worth about $34,000. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.